Prostate Cancer Screening

Edward Morello Excerpts

Monday 26th October 2026 Westminster Hall

[John Lamont]

The right hon. Gentleman makes an important point. I will come on to the importance of ensuring that we get a UK-wide approach, because there are subtle differences among the devolved nations.

The UK Government decision to accept the UK NSC’s final recommendation in England—to provide a PSA test every two years to men aged 45 to 61 with pathogenic BRCA2 variant and a relevant family history of breast, ovarian, pancreatic or prostate cancer—is a significant step forward, and roll-out is expected from 2027. BRCA1 carriers, however, are excluded, and BRCA2 carriers must also meet the family history criterion. The Department of Health and Social Care estimates estimates that only around 1,500 men in England will be eligible, and acknowledges that most prostate cancer cases will therefore fall outside the programme.

The final recommendation also falls well short of what Members from across the House have called for. In November 2025, a cross-party letter signed by more than 120 MPs, hand delivered to the Health Secretary by my right hon. Friend the Member for Richmond and Northallerton (Rishi Sunak), called on the Government to act for the men at greatest risk: black men; men with a family history of prostate, breast or ovarian cancer; and BRCA1 and BRCA2 carriers. Its message was clear: perfection must not be the enemy of progress. The concern raised by those MPs reinforces the central question that the petition addresses: is the current screening programme too narrow?

[Edward Morello (West Dorset) (LD)]

As somebody who has the BRCA2 genetic abnormality, I will be eligible for the extra screening that the hon. Gentleman outlined. Unfortunately, too many men are delayed in getting screened, especially in rural and deprived areas, and the delays result in prostate cancer being identified far later. Although I am grateful to the Government for including me in the screening, does the hon. Gentleman agree that more must be done to inform men of the need for regular screening to avoid it being caught so late?

[John Lamont]

The hon. Member makes an important point about awareness and the challenge in rural areas. I will come to that later in my speech.

I am pleased that my right hon. Friend the Member for Richmond and Northallerton is present, having done so much to advance this issue. As Prime Minister, his Government backed the £42 million Transform trial, providing £16 million of Government funding to examine different approaches to prostate cancer screening.

For the benefit of Members who are not aware, Transform is the largest prostate cancer screening trial in two decades. Designed and led by Prostate Cancer UK, with Government funding through the National Institute for Health and Care Research, it is comparing combinations of PSA blood tests, fast MRI scans and genetic saliva tests to find the safest and most effective way to detect prostate cancer before it becomes incurable. Crucially, it is designed to include far more black men than previous trials. With further Government funding announced this year, it is now worth around £60 million, and its first-stage results are expected before the end of 2027.

My right hon. Friend has since become an ambassador for Prostate Cancer Research and has called for a targeted national screening programme for the groups most at risk. Prostate Cancer Research says that the final UK NSC recommendation

“falls short of what is needed”,

arguing that too many high-risk men remain outside the programme.